Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials
Authors' conclusion
In this post hoc analysis, tirzepatide was associated with superior glycemic control compared with insulin, irrespective of baseline glycemic pattern.
Study context
- Population
- People with T2D and different baseline glycemic patterns: subgroups low fasting serum glucose (FSG)/low PPG, low FSG/high PPG, high FSG/low PPG, high FSG/high PPG, defined by median values of fasting serum glucose and postprandial glucose
- Comparison
- Tirzepatide vs basal insulin
- Primary endpoint
- Change from baseline in glycemic parameters (HbA1c, FSG, PPG) by baseline FSG/PPG subgroup
- Follow-up
- Week 52
Methodological detailssubgroup analysis
- Subgroup analysis
Primary result
As reported in the abstract
HbA1c, FSG and PPG change by FSG/PPG subgroup · baseline to week 52
- All tirzepatide doses and basal insulins decreased HbA1c, FSG and PPG in all subgroups
- P < 0.05
- Within each subgroup, HbA1c and PPG decreases greater with tirzepatide than insulin
- P < 0.05
Original publication
Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials. Diabetes Care. Published 26 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →